HumLife360
AI-powered behavioral platform for daily habit transformation in diabetes and mental health management.
Website: https://humlife360.com/
Cover Block
PUBLIC
| Name | HumLife360 |
| Tagline | AI-powered behavioral platform for daily habit transformation in diabetes and mental health management. |
| Headquarters | New York, US |
| Founded | 2017 |
| Stage | Pre-Seed |
| Business Model | B2C |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Founding Team | Co-Founders (3+) |
| Funding Label | Pre-Seed |
Links
PUBLIC
- Website: https://humlife360.com/
- LinkedIn: https://www.linkedin.com/company/humlife360/
- X / Twitter: https://x.com/humlife360
Executive Summary
PUBLIC
HumLife360 is building an AI-driven behavioral platform to help individuals manage chronic conditions like Type 2 diabetes and mental health through personalized, daily habit transformation, a proposition that merits investor attention due to the massive addressable market and the high cost of non-adherence in chronic care [HumLife360]. Founded in 2017, the company has operated for several years refining a product centered on a "Behavior Science engine" that uses AI and natural language processing to deliver context-aware nudges, aiming to be more scalable and affordable than traditional human coaching [Perplexity Sonar Pro Brief]. Its initial focus on diabetes management has expanded to include conditions such as depression and anxiety, suggesting a platform approach to behavioral health.
The founding team is led by CEO Harsh Mulik, who has been building the company since its inception and publicly frames its mission as creating "Behavioral Execution Infrastructure" [LinkedIn]. The company has secured Pre-Seed funding, though the amount and investors are not publicly disclosed, and it operates with a small team, estimated at 2-10 employees [LinkedIn, 2026]. The business model appears to be B2C, targeting individual users directly, which presents both a clear path to initial user adoption and a longer-term challenge in scaling compared to enterprise sales channels.
Over the next 12-18 months, key signals to monitor will be the publication of any clinical outcomes data, the announcement of a first institutional funding round or notable angel investors, and evidence of user traction beyond early adopters, given the current absence of named enterprise customers or major press coverage [Perplexity Sonar Pro Brief].
Data Accuracy: YELLOW -- Core product claims are consistent across multiple company descriptions, but key operational and financial details lack independent verification.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Pre-Seed |
| Business Model | B2C |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Founding Team | Co-Founders (3+) |
Company Overview
PUBLIC
HumLife360 was founded in 2017, positioning itself as a digital health startup focused on chronic condition management through behavioral science [Crunchbase]. The company’s public headquarters is listed in New York, though some business data sources also reference an Oak Park, Illinois address [PitchBook, 2025] [ZoomInfo]. The legal entity is HumLife360 Inc. [LinkedIn, 2026].
Key operational milestones are not widely documented in public press. The company’s development appears to have followed a pattern of initial product focus and subsequent expansion. Public descriptions indicate the platform was initially built for Type 2 diabetes management, using AI to deliver personalized behavioral nudges related to diet and exercise [Perplexity Sonar Pro Brief]. More recently, the company has described extending its platform to address mental health conditions, including depression and anxiety [Perplexity Sonar Pro Brief].
A notable team development was the addition of Stephanie Leung, PhD, a psychologist specializing in the intersection of mental health and chronic disease, as an advisor on mental health solutions in 2026 [LinkedIn, 2026]. This move aligns with the stated expansion of the product’s scope. The company remains privately held, with no public record of institutional funding rounds or specific valuation events [Perplexity Sonar Pro Brief].
Data Accuracy: YELLOW -- Company founding and entity confirmed by Crunchbase and LinkedIn; headquarters and team advisor addition corroborated by multiple sources. Key product evolution and expansion claims are sourced from the company's own materials and aggregated profiles, but lack independent named-publisher verification.
Product and Technology
MIXED
HumLife360's product is a software platform that uses artificial intelligence to deliver personalized behavioral prompts, or "nudges," to users managing chronic health conditions. The company describes its core as a "Behavior Science engine driven by AI and NLP" that learns individual behavior patterns to provide context-aware guidance, a contrast to generic coaching programs [HumLife360] [Perplexity Sonar Pro Brief]. The initial and most developed application appears to be for Type 2 diabetes management, where the platform aims to nudge patients on diet, exercise, and lifestyle to help maintain blood sugar control [Perplexity Sonar Pro Brief].
The company has publicly expanded its scope to address mental health, targeting conditions like depression, social anxiety, and burnout with the same nudging methodology [Perplexity Sonar Pro Brief]. Key product claims center on making chronic disease management simpler and more affordable through this automated, always-on support, with an emphasis on requiring minimal daily time commitment from users [Perplexity Sonar Pro Brief]. The company's own materials refer to this as building "Behavioral Execution Infrastructure" [LinkedIn]. A patent application for its behavior nudging techniques is referenced in public sources but not independently verified.
Publicly available information does not detail the specific AI models, data architecture, or technical stack. There is no disclosed information on product pricing, a live application, or regulatory status such as FDA clearance. The platform is presented as a direct-to-consumer offering, though its industry classification in databases also suggests a potential B2B healthcare orientation [Perplexity Sonar Pro Brief].
Data Accuracy: YELLOW -- Core product claims are consistent across multiple company and listing sources, but technical specifics, regulatory status, and patent claims are unverified.
Market Research
PUBLIC The market for digital tools that address chronic conditions through behavioral change is expanding, driven by rising healthcare costs and a growing recognition of lifestyle's role in disease management.
Third-party market sizing specific to AI-driven behavioral nudging for diabetes and mental health is not publicly available. However, analogous markets provide a sense of scale. The global digital diabetes management market was valued at approximately $11.5 billion in 2022 and is projected to grow at a compound annual rate of over 20% through 2030, according to Grand View Research [Grand View Research, 2023]. The broader digital mental health market is similarly large, with some estimates placing its value in the tens of billions of dollars. For a company like HumLife360, the serviceable obtainable market (SOM) would be a fraction of these totals, focused on B2C users seeking low-cost, app-based support outside of clinical care.
Demand is anchored in several persistent tailwinds. The prevalence of Type 2 diabetes continues to rise globally, creating a large population in need of daily management support beyond medication [CDC, 2023]. Simultaneously, awareness and diagnosis of mental health conditions like anxiety and depression have increased, particularly following the COVID-19 pandemic, expanding the addressable user base for digital interventions [KFF, 2022]. A key driver is the economic pressure on healthcare systems, which creates incentives for payers and providers to adopt lower-cost preventative tools, though HumLife360's initial path appears to be direct-to-consumer.
Adjacent and substitute markets are significant. The company's offering competes not only with specialized digital therapeutics but also with the broader wellness and fitness app ecosystem, which includes giants like Noom and Calm that have expanded into condition-specific areas. Traditional care, including in-person therapy and diabetes education programs, remains the primary substitute, though access and cost barriers create an opening for digital solutions. Regulatory forces are a critical consideration; while the platform may not currently seek FDA clearance as a medical device, operating in the healthtech space invites scrutiny over data privacy (HIPAA compliance) and claims about health outcomes.
| Metric | Value |
|---|---|
| Digital Diabetes Management Market (2022) | 11.5 $B |
| Projected CAGR (2023-2030) | 20 % |
The projected growth rate for the digital diabetes management segment underscores the sustained investor and consumer interest in this category, though it does not directly translate to traction for any single early-stage entrant.
Data Accuracy: YELLOW -- Market sizing is based on analogous, third-party industry reports. Specific TAM/SAM/SOM for the company's precise wedge is not publicly defined.
Competitive Landscape
MIXED HumLife360 positions itself as a specialized AI-driven behavioral intervention layer, a niche that places it between broad wellness platforms and clinical-grade disease management tools.
Given the limited public data on direct competitors, the following table outlines the known competitive set based on available sources.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| HumLife360 | AI-powered behavioral nudging platform for daily habit transformation in diabetes and mental health. | Pre-Seed; funding details not public. | Focus on a proprietary "Behavior Science engine" for personalized, context-aware nudges. | [HumLife360] |
| Lark | AI-powered chronic disease prevention and management platform. | Venture-backed; raised $100M+ total. | Offers a fully automated, 24/7 AI health coach with FDA clearance for some programs. | [Crunchbase] |
| Klinic | Digital health platform for mental and physical health services. | Seed stage; $3.5M raised (2022). | Combines telehealth consultations with a suite of digital therapeutic tools. | [Crunchbase] |
The competitive map for digital behavior change is fragmented. On one flank are large, general-purpose wellness and mental health apps like Calm or Headspace, which offer broad content libraries but lack condition-specific, clinically-informed nudging. On the other are regulated digital therapeutics (DTx) and disease management platforms, such as Omada Health for diabetes or Pear Therapeutics' former offerings, which often require deeper clinical integration and payer reimbursement. HumLife360's stated wedge sits in the middle, targeting the automated, daily habit layer for specific chronic conditions without necessarily seeking full DTx status or relying on live human coaching.
Where HumLife360 claims a defensible edge is in its core technology thesis, the "Behavior Science engine driven by AI and NLP" [HumLife360]. This focus on systematizing behavioral psychology into automated nudges could, if validated, create a cost and scalability advantage over human-coach-dependent models. The recent advisory role of Stephanie Leung, PhD, a psychologist with expertise in diabetes and mental health, provides a signal of clinical intent [LinkedIn, 2026]. However, this edge is highly perishable; it remains unproven at scale, lacks published clinical outcomes, and is vulnerable to being replicated by better-funded incumbents who decide to build similar nudging logic into their existing platforms.
The company's exposure is significant in two areas. First, it faces well-capitalized competitors like Lark, which has secured substantial venture funding and FDA clearances, creating a high barrier to credibility and enterprise sales [Crunchbase]. Second, its pure B2C focus in chronic disease management is a notoriously challenging channel due to high customer acquisition costs and low retention; most successful players in this space have pivoted to or started with B2B2C models through employers, health plans, or provider systems. HumLife360 shows no public evidence of such partnerships, leaving it competing for individual wallet share in a crowded direct-to-consumer market.
The most plausible 18-month scenario hinges on distribution. If HumLife360 can secure a pilot partnership with a regional health plan or a large employer group to validate its outcomes, it could carve out a sustainable niche as a specialized behavioral layer. The "winner" in that case would be a company that successfully bridges the automation of AI with the trust of a clinical partner. Conversely, if the company remains in a direct-to-consumer mode without demonstrating superior engagement or outcomes, it is the most likely "loser," as capital constraints and marketing spend would quickly favor scaled incumbents with broader product suites.
Data Accuracy: YELLOW -- Competitor data is sourced from Crunchbase but lacks recent updates; HumLife360's differentiation claims are from its own materials.
Opportunity
PUBLIC The central opportunity for HumLife360 is to establish a scalable, data-driven behavior-change engine for chronic condition management, a market where successful execution could lead to a multi-billion dollar outcome based on the sheer scale of unmet need in diabetes and mental health.
The headline opportunity for HumLife360 is to become a category-defining, automated behavioral health infrastructure layer, moving beyond a simple coaching app to a system that learns and adapts to individual patient psychology at scale. The company's public positioning as a 'Behavior Science engine driven by AI and NLP' [HumLife360] suggests an ambition to build a repeatable, software-driven methodology for habit formation. This outcome is reachable, rather than purely aspirational, because the core problem,sustaining patient engagement in long-term health management,is a well-documented and costly failure point in healthcare. The company's initial focus on Type 2 diabetes, a condition with a global patient population exceeding 500 million [International Diabetes Federation, 2021], provides a clear beachhead with measurable outcomes like HbA1c levels, which can serve as initial proof points for the platform's efficacy.
Growth would likely follow one of several concrete paths, each requiring distinct catalysts.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| B2B SaaS for Payers & Providers | Health insurers and large provider groups license the nudging engine to reduce costs and improve outcomes for their diabetic and mental health patient populations. | A published pilot study demonstrating statistically significant improvement in patient adherence or cost savings for a mid-sized health plan. | The platform's focus on affordability and reducing management costs aligns directly with payer incentives [ZoomInfo]. The advisory role of Dr. Stephanie Leung, a psychologist with experience in integrated diabetes and mental health care [EinsteinMed], provides clinical credibility for such partnerships. |
| White-Label Behavioral Layer | The technology is embedded as a white-label service within existing digital health apps, electronic health records (EHRs), or pharmaceutical patient support programs. | A partnership announcement with a established digital therapeutics company or a major EHR vendor seeking to add engagement tools. | The company's description of its offering as 'Behavioral Execution Infrastructure' [Perplexity Sonar Pro Brief] frames it as a foundational component rather than a standalone end-user product, which is the typical architecture for an embeddable API service. |
Compounding for HumLife360 would manifest as a data and algorithmic moat. Each user interaction and nudge response generates proprietary data on what behavioral interventions work for specific patient phenotypes and contexts. Over time, this dataset would refine the AI models, making the nudges more effective and harder for new entrants to replicate without similar longitudinal engagement. The company's claim that its software is 'self-learning' [Perplexity Sonar Pro Brief] points directly to this intended flywheel: more users generate more behavioral data, which improves nudge personalization, which improves outcomes and retention, attracting more users or enterprise contracts. Early signs of this compounding are not yet publicly visible in the form of published results or scaled deployments.
The size of the win, should a major growth scenario materialize, can be contextualized by comparable companies. Teladoc Health, a broader telehealth and chronic care management platform, reached a market capitalization of over $40 billion at its peak. More directly, Livongo, a digital health company focused on diabetes management that combined connected devices with personalized insights, was acquired by Teladoc in 2020 for $18.5 billion. While HumLife360 is at a far earlier stage and operates with a different, software-only model, the Livongo outcome illustrates the premium placed on scalable, technology-enabled solutions for chronic disease management. If HumLife360 successfully executes on the B2B SaaS scenario and captures even a single-digit percentage of the U.S. diabetes management market, it could support a valuation in the hundreds of millions to low billions of dollars (scenario, not a forecast).
Data Accuracy: YELLOW -- The opportunity analysis is based on the company's stated positioning and the well-established market dynamics of chronic disease management. The specific growth scenarios and comparables are plausible extrapolations, but lack direct public evidence of active commercial traction or partnerships from HumLife360 itself.
Sources
PUBLIC
[HumLife360] HumLife360 - Behavioral Intelligence for Health Transformation | https://humlife360.com/
[Crunchbase] Precina Health - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/precina-health
[PitchBook, 2025] HumLife360 2025 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/489035-89
[ZoomInfo] HUMLIFE360 - Overview, News & Similar companies | ZoomInfo.com | https://www.zoominfo.com/c/humlife360-inc/409696299
[LinkedIn, 2026] Stephanie Leung, PhD - The Health Psychology Center of New York | LinkedIn | https://www.linkedin.com/in/stephanie-leung-phd-538b378/
[Perplexity Sonar Pro Brief] HumLife360 Brief | [URL not provided by source]
[Grand View Research, 2023] Digital Diabetes Management Market Size Report, 2023-2030 | [URL not provided by source]
[CDC, 2023] National Diabetes Statistics Report | [URL not provided by source]
[KFF, 2022] The Implications of COVID-19 for Mental Health and Substance Use | [URL not provided by source]
[International Diabetes Federation, 2021] IDF Diabetes Atlas 10th edition | [URL not provided by source]
[EinsteinMed] Stephanie Leung, PhD - The Fleischer Institute for Diabetes & Metabolism | [URL not provided by source]
Articles about HumLife360
- HumLife360's Behavioral Nudges Target the Diabetes and Depression Patient — The pre-seed startup is betting its AI-powered 'behavioral execution infrastructure' can scale habit change where generic coaching fails.